Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Dysphagia, QoL and Attitudes Towards PEG in ALS Patients Primary and study completion pushed from Sep 30, 2026 to Dec 30, 2026
- Minor: Moisturization and Skin Hydration Study Primary completion pushed from Dec 2026 to May 2027
- Minor: Robot-Aided Off-Axis Neuromuscular Training for Knee OA Primary completion pushed from Jun 1, 2029 to Oct 31, 2029
- Minor: Use of AI Chatbots for Mental Health Primary completion pushed from Oct 2026 to Dec 2026
- Minor: Extracorporeal Shock Wave Therapy, LASER Therapy and Cryotherapy in Patients Having Sacroiliitis Primary and study completion pushed from Sep 10, 2026 to Dec 10, 2026
- Minor: Brief Mindfulness Training With Vagal Nerve Stimulation on Alcohol Cue Reactivity Among Young Adult Heavy Drinkers Primary and study completion pushed from Aug 2026 to Dec 31, 2026
- Minor: 5 vs 8 cmH₂O PEEP on Respiratory Mechanics in Prone Lumbar Surgery Primary completion pushed from Sep 2, 2026 to Jan 31, 2027
- Minor: Consciousness Studies and Cardiovascular Health Primary and study completion pushed from Oct 2028 to Dec 2028
- Minor: Ultrasound Detection of Body Composition in Critical Care Primary completion pushed from Oct 25, 2026 to Dec 25, 2026
- Minor: Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Trial sites expanded: 4 → 7 locations
- Minor: EIK1001 in Combination With Pembrolizumab and Chemotherapy · Stage 4 Non-Small Cell Lung Cancer Trial sites expanded: 42 → 52 locations
- Minor: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events Trial sites expanded: 252 → 261 locations
- Minor: ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Trial sites expanded: 6 → 9 locations
- Minor: Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) Trial sites expanded: 124 → 129 locations
- Minor: Inclisiran to Prevent Cardiovascular (CV) Events · Established Cardiovascular Disease Trial sites expanded: 983 → 989 locations
- Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Trial sites expanded: 4 → 7 locations
- Minor: Petrelintide · Overweight or Obesity and Established Cardiovascular Disease Trial sites expanded: 3 → 11 locations
- Minor: Fixed Doses of SEP-363856 · Generalized Anxiety Disorder Trial sites expanded: 17 → 27 locations
- Minor: Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment · Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Trial sites expanded: 34 → 69 locations
- Minor: Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Trial sites expanded: 7 → 12 locations
- Minor: NX-5948 · CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) Trial sites expanded: 43 → 47 locations
- Minor: QCZ484 in Hypertensive Patients Trial sites expanded: 25 → 46 locations
- Minor: ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 14 → 19 locations
- Minor: SRP-1005 · Huntington's Disease Trial sites expanded: 4 → 8 locations
- Minor: Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Trial sites expanded: 0 → 13 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates